Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.7 |
mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | 0.018 | 0.7 |
mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.7 |
mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.7 |